Spelling suggestions: "subject:"alcoholic hepatitis"" "subject:"lcoholic hepatitis""
1 |
Genome-Wide Studies of Transcriptional Regulation in Human Liver Cells by High-throughput SequencingBysani, Madhusudhan Reddy January 2013 (has links)
The human genome contains slightly more than 20 000 genes that are expressed in a tissue specific manner. Transcription factors play a key role in gene regulation. By mapping the transcription factor binding sites genome-wide we can understand their role in different biological processes. In this thesis we have mapped transcription factors and histone marks along with nucleosome positions and RNA levels. In papers I and II, we used ChIP-seq to map five liver specific transcription factors that are crucial for liver development and function. We showed that the mapped transcription factors are involved in metabolism and other cellular processes. We showed that ChIP-seq can also be used to detect protein-protein interactions and functional SNPs. Finally, we showed that the epigenetic histone mark studied in paper I is associated with transcriptional activity at promoters. In paper III, we mapped nucleosome positions before and after treatment with transforming growth factor β (TGFβ) and found that many nucleosomes changed positions when expression changed. After treatment with TGFβ, the transcription factor HNF4α was replaced by a nucleosome in some regions. In paper IV, we mapped USF1 transcription factor and three active chromatin marks in normal liver tissue and in liver tissue of patients diagnosed with alcoholic steatohepatitis. Using gene ontology, we as expected identified many metabolism related genes as active in normal samples whereas genes in cancer pathways were active in steatohepatitis tissue. Cancer is a common complication to the disease and early signs of this were found. We also found many novel and GWAS catalogue SNPs that are candidates to be functional. In conclusion, our results have provided information on location and structure of regulatory elements which will lead to better knowledge on liver function and disease.
|
2 |
Insights into the role of CTP:phosphocholine cytidylyltransferase-alpha in hepatic lipid metabolism and cellular integrityNiebergall, Lorissa J Unknown Date
No description available.
|
3 |
A study of non-alcoholic fatty liver disease (NAFLD) in South African patients and analysis of candidate genes in insulin resistance and fatty acid oxidation.Kruger, F. C. 12 1900 (has links)
Thesis (PhD (Medicine. Internal Medicine))--Stellenbosch University, 2008. / Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in Western
countries, extending from steatosis (FLD) to steatohepatitis (NASH). Differentiation between
NASH and nonprogressive NAFLD is difficult on clinical grounds therefore a need exists to
identify reliable biomarkers of disease progression.
The aims of the study were 1) to describe the disease profile of NAFLD/NASH in South African
patients of the Western Cape, 2) to investigate the metabolic derangements associated with this
condition, including insulin resistance, lipid abnormalities and liver fibrogenesis, and 3) to
assess the possible involvement of candidate genes in relation to the disease phenotype in the
patient cohort.
A total of 233 patients (73% female) were enrolled in this study, consisting of 69% Cape
Coloured, 25% Caucasian, 5% Black and 1% Asian individuals. All subjects were obese or
overweight based on the assessment of body mass index (BMI). Screening for NAFLD identified
182 patients (87%) with ultrasonographical evidence of fatty infiltration and/or hepatomegaly.
Liver biopsies were performed on patients with persistently abnormal liver functions and/or
hepatomegaly. NAFLD was confirmed histologically in 111 patients of whom 36% had NASH
and 17% advanced liver fibrosis. None of the Black patients had advanced fibrosis.
|
4 |
Untersuchungen zur therapeutischen Anwendung mesenchymaler Stammzellen bei chronischen Lebererkrankungen am Beispiel der Nicht-alkoholischen SteatohepatitisWinkler, Sandra 13 January 2015 (has links) (PDF)
Die Nicht-alkoholische Steatohepatitis (NASH), gehörig zu der Gruppe der chronischen Lebererkrankungen als eine schwere Form der Nicht-alkoholischen Fettleber-erkrankungen (NAFLD), nimmt in ihrer Prävalenz ständig zu. Gründe dafür sind u.a. eine gesteigerte Nahrungsaufnahme sowie Veränderungen der Nahrungszusammen-setzung. Es kommt zur Ausbildung einer Steatose, die sich unter Mitwirkung verschie-dener Einflussfaktoren zur Steatohepatitis weiterentwickeln kann, wobei die Pathoge-nese noch nicht genau verstanden ist. Die Nicht-alkoholische Steatohepatitis geht oft einher mit Insulinresistenz und starkem Übergewicht. Die Folgen für die Leber sind Funktionseinschränkungen und –verlust, hervorgerufen durch eine massive Akkumula-tion von Triglyzeriden in den Hepatozyten, Entzündungsprozesse sowie einem fibro-tischen Umbau der Leber. Im fortgeschritten Stadium wird eine Lebertransplantation unausweichlich, die jedoch aufgrund des zunehmenden Mangels an Spenderorganen oft nicht möglich ist. Eine Alternative bietet die Transplantation mesenchymaler Stammzellen (MSC). MSC können in vitro in leberzellähnliche Zellen differenziert wer-den und weisen dabei essentielle hepatozytäre Eigenschaften auf, wodurch sie als möglicher Ersatz bzw. als Überbrückungstherapie bis zur Lebertransplantation in Frage kommen. Die vorliegende Arbeit beschäftigte sich mit dieser Fragestellung. Dazu wur-de ein Tiermodell der NASH mittels Methionin-Cholin-defizienter Diät (MCD-Diät) etab-liert und die Transplantation von hepatozytär differenzierten MSC durchgeführt. An-hand spezifischer zellulärer und biochemischer Marker der NASH konnte die Wirkung des Zelltransplantats auf die Empfängerleber analysiert werden. Es hat sich gezeigt, dass die MSC einen anti-inflammatorischen, anti-fibrotischen und pro-proliferativen Einfluss auf das Empfängerparenchym hatten und somit zur Verbesserung der Symptomatik der NASH beitrugen.
|
5 |
Diet-induced dyslipidemia drives store-operated Ca2+ entry, Ca2+ dysregulation, non-alcoholic steatohepatitis, and coronary atherogenesis in metabolic syndromeNeeb, Zachary P. January 2010 (has links)
Thesis (Ph.D.)--Indiana University, 2010. / Title from screen (viewed on July 21, 2010). Department of Cellular and Integrative Physiology, Indiana University-Purdue University Indianapolis (IUPUI). Advisor(s): Michael Sturek, Jeffrey A. Breall, Robert V. Considine, Alexander Obukhov, Johnathan D. Tune. Includes vitae. Includes bibliographical references (leaves 212-240).
|
6 |
The Association Between Non-Alcoholic Fatty Liver Disease and Atrial Fibrillation: A Meta-AnalysisWijarnpreecha, Karn, Boonpheng, Boonphiphop, Thongprayoon, Charat, Jaruvongvanich, Veeravich, Ungprasert, Patompong 01 October 2017 (has links)
The association between non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) has been suggested by recent epidemiological studies although the results were inconsistent. This meta-analysis was conducted to summarize all available data. Methods A comprehensive literature review was conducted using MEDLINE and EMBASE database through May 2017 to identify all studies that reported the risk of AF among patients with NAFLD versus those without NAFLD. Effect estimates from each study were extracted and combined together using the random-effect, generic inverse variance method of DerSimonian and Laird. Results Of 1009 studies, 5 studies (two cross-sectional studies and three cohort studies) with 238,129 participants met the eligibility criteria and were included in the meta-analysis. The risk of AF in patients with NAFLD was significantly higher than subjects without NAFLD with the pooled risks ratio of 2.06 (95% confidence interval, 1.10–3.85). The statistical heterogeneity was high with an I2 of 78%, which was the major limitation of this meta-analysis. Conclusions A significantly increased risk of AF among patients with NAFLD was demonstrated in this study.
|
7 |
The role of CFP1 in maintaining liver homeostasis in a murine modelChittajallu, Nandita 09 June 2017 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / CXXC finger protein 1 (CFP1) is an epigenetic regulator of H3K4 and cytosine
methylation. Due to its role in establishing and maintaining methylation patterns, CFP1
determines whether DNA is found in its euchromatin or heterochromatin state and as
such whether genes are transcriptionally active or inactive. In stem cells, deficiency of
CFP1 results in inability to differentiate and in murine embryos it results in periimplantation
death. Despite the demonstrated importance in developing tissue, the role of
CFP1 in mature tissues, such as the liver, has yet to be elucidated. This study examined
the role of CFP1 in maintaining liver homeostasis under conditions involving
hepatocellular stress by examining liver regeneration, pregnancy-induced hepatomegaly,
and non-alcoholic steatohepatitis (NASH) disease progression. The liver’s ability to
recover was analyzed through liver:body mass ratios, blood serum analysis, liver
histology, and qualitative observations. Deficiency of CFP1 in the livers of animals
subjected to partial hepatectomies (PH) resulted in decreased liver regeneration capacity
with liver mass restoration becoming significantly different starting at 48H post-PH and
remaining so until 10D post-PH. This decreased regeneration appeared to be the result of
reduced hepatocyte mitosis. Mouse dams lacking hepatic CFP1 mated with males
expressing CFP1 displayed a proclivity for dystocia. Mice subjected to a fast food diet
resulting in NASH while lacking hepatic CFP1 experienced decreased weight gain and
hepatic lipid accumulation compared to their CFP1 expressing counterparts. Through
these three studies, the critical role of CFP1 for the maintenance of liver homeostasis was
demonstrated.
|
8 |
Diet-induced dyslipidemia drives store-operated Ca2+ entry, Ca2+ dysregulation, non-alcoholic steatohepatitis, and coronary atherogenesis in metabolic syndromeNeeb, Zachary P. 21 July 2010 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / Risk of coronary artery disease (CAD), the leading cause of death, greatly increases in metabolic syndrome. Metabolic syndrome (MetS; obesity, insulin resistance, glucose intolerance, dyslipidemia, and hypertension) is increasing in prevalence with sedentary lifestyles and poor nutrition. Non-alcoholic steatohepatitis (NASH; i.e. MetS liver) is progressive and decreases life expectancy, with CAD as the leading cause of death. Pathogenic Ca2+ regulation transforms coronary artery smooth muscle from a healthy, quiescent state to a diseased, proliferative phenotype thus majorly contributing to the development of CAD. In particular, store-operated Ca2+ entry (SOCE) in vascular smooth muscle is associated with atherosclerosis. Genetic predisposition may render individuals more susceptible to Ca2+ dysregulation, CAD, NASH, and MetS. However, the metabolic and cellular mechanisms underlying these disease states are poorly understood. Accordingly, the goal of this dissertation was to investigate the role of dyslipidemia within MetS in the development of Ca2+ dysregulation, CAD, and NASH. The overarching hypothesis was that dyslipidemia within MetS would be necessary for induction of NASH and increased SOCE that would primarily mediate development of CAD. To test this hypothesis we utilized the Ossabaw miniature swine model of MetS. Swine were fed one of five diets for different lengths of time to induce varying severity of MetS. Lean swine were fed normal maintenance chow diet. F/MetS swine were fed high Fructose (20% kcal) diet that induced normolipidemic MetS. TMetS were fed excess high Trans-fat/cholesterol atherogenic diet that induced mildly dyslipidemic MetS and CAD. XMetS were TMetS swine with eXercise. DMetS (TMetS + high fructose) were moderately dyslipidemic and developed MetS and extensive CAD. sDMetS (Short-term DMetS) developed MetS with mild dyslipidemia, but no CAD. MMetS (Mixed-source-fat/cholesterol/fructose) were severely dyslipidemic, exhibited NASH, and developed severe CAD. Dyslipidemia in MetS predicted NASH severity (all groups < DMetS << MMetS), CAD severity (i.e. Lean, F/MetS, sDMetS < XMetS < TMetS < DMetS < MMetS), and was necessary for STIM1/TRPC1-mediated SOCE, which preceded CAD. Exercise ameliorated SOCE and CAD compared to TMetS. In conclusion, dyslipidemia elicits TRPC1/STIM1 SOCE that mediates CAD, is necessary for and predictive of NASH and CAD, and whose affects are attenuated by exercise.
|
9 |
A Novel Role for CEACAM1 in Hepatic Stellate Cell Activation in the Progression of Non-Alcoholic SteatohepatitisGhosh, Sumona 30 May 2012 (has links)
No description available.
|
10 |
Progression et tests diagnostiques de la stéatose hépatique non alcoolique / Progression and diagnostic methods in non-alcoholic fatty liver diseaseFedchuk, Larysa 30 September 2014 (has links)
La stéatose hépatique non alcoolique, regroupant la stéatose isolée (NAFLD) et la stéatohépatite non-alcoolique (NASH), est un enjeu de santé publique mondial en raison d’une incidence croissante, en grande partie expliquée par l’augmentation de la prévalence du diabète et de l’obésité. La stéatose hépatique prédit la survenue des complications métaboliques associées à l’insulinorésistance, comme le diabète ou les événements cardiovasculaires. La connaissance de l’histoire naturelle de la NAFLD comporte encore de nombreuses incertitudes. Actuellement le modèle explicatif repose sur une dichotomie entre la stéatohépatite (NASH), qui peut progresser vers la cirrhose et la stéatose isolée ou avec inflammation minime (NAFL) qui jusqu'à présent était considérée comme une condition non évolutive ne progressant pas vers la cirrhose et n'augmentant pas la morbi-mortalité d'origine hépatique. Cette dichotomie conditionne en grande partie la prise en charge de ces patients, ceux avec NAFL étant souvent rassurés par le praticien quant à leur devenir et ne bénéficiant pas d'une surveillance hépatique spécifique. La ponction biopsie du foie est considérée comme un examen de référence, mais son usage en pratique clinique reste limité en raison d’effets indésirables, d’erreurs d'échantillonnage et de la variabilité d’interprétation inter-observateur. Les méthodes non invasives de lésions hépatiques sont devenues une vraie alternative à la biopsie du foie pour la prise en charge des patients ayant une maladie chronique du foie, au cours des dix dernières années. / Non-alcoholic fatty liver disease (NAFLD) covers a spectrum ranging from isolated steatosis to non-alcoholic steatohepatitis (NASH) and is becoming one of the most frequent causes of chronic liver disease, mainly because of its close association with the worldwide epidemic of diabetes and obesity. Liver steatosis can predict the occurrence of metabolic complications associated with insulin resistance, such as diabetes and cardiovascular events. Our understanding of the natural history of NAFLD is still incomplete. Currently, the explicative model is based on a dichotomy between steatohepatitis, considered the progressive form of the disease, which can lead to cirrhosis and isolated steatosis with or without minimal inflammation, which is considered a non-progressive condition that does not impact overall survival or result in liver-related mortality and morbidity. This dichotomy largely determines the management of NAFLD patients: patients without steatohepatitis usually do not undergo specific monitoring for liver disease progression. Liver biopsy is considered the reference diagnostic method but its implementation in clinical practice remains limited due to procedure complexity, invasiveness, cost, potential complications, sampling error and inter-observer variability. Non-invasive methods of hepatic injury have become a real alternative to liver biopsy for the diagnosis of patients with chronic liver disease in the past decade. The aims of this thesis were: 1) to better understand the histological course of the disease, to better identify patients at risk of histological progression based on initial histological findings and to establish a correlation between histological changes and the course of metabolic co-morbidities often associated with NAFLD : 2) to establish factors associated with short-term variability of repeated measurements of elastometry in patients with chronic liver diseases in order to understand how this non invasive procedure can be used for patient monitoring 3) to determine the diagnostic value and limitations of several steatosis biomarkers using liver biopsy as a reference standard in a large cohort of patients with suspected NAFLD. Our study shows that a fraction of patients with isolated steatosis can unambiguously evolve towards well-defined steatohepatitis, and in some of them, bridging fibrosis. The presence of mild lobular inflammation or any amount of fibrosis substantially increases the risk of histological progression in the mid-term while those with steatosis alone are at lowest risk. Patients with disease progression experienced a deterioration of cardio-metabolic risk factors. Our data if validated by independent studies, allow for better stratification of patients at risk of disease progression. The results of this study favor a change in the practices of monitoring and risk assessment of patients with steatosis but without steatohepatitis.
|
Page generated in 0.0908 seconds